Drugs / CD19 CAR-T
last change Feb 2026 re-read 2 minutes ago

CD19 CAR-T

Cell therapy targets CD19

Developed for
autoimmune disease · B-cell acute lymphoblastic leukemia · B-cell non-Hodgkin lymphoma · acute lymphoblastic leukemia · non-Hodgkin lymphoma · acute leukemia · acute myeloid leukemia · B-cell adult acute lymphocytic leukemia
+9 more · B-cell neoplasm · childhood acute lymphoblastic leukemia · follicular lymphoma · lupus nephritis · lymphoid leukemia · lymphoma · mantle cell lymphoma · plasma cell myeloma · therapy-related myeloid neoplasm
Investigated by
Hebei Senlang Biotechnology Inc., Ltd. · Beijing Boren Hospital · Bioray Laboratories · Chinese PLA General Hospital · Shenzhen University General Hospital · Beijing Lu Daopei Hospital
+22 more · Gracell Biotechnology Ltd. · Hebei Taihe Chunyu Biotechnology Co., Ltd · Hebei Yanda Ludaopei Hospital · Henan Cancer Hospital · Innovative Cellular Therapeutics Co., Ltd. · Institute of Hematology & Blood Diseases Hospital, China · Jichi Medical University · Nanfang Hospital, Southern Medical University · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Second Affiliated Hospital of Suzhou University · Second Affiliated Hospital, School of Medicine, Zhejiang University · Second Xiangya Hospital of Central South University · Shanghai Longyao Biotechnology Inc., Ltd. · Shanghai Tong Ren Hospital · Shenzhen Second People's Hospital · Shenzhen University · Takara Bio Inc. · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · The Beijing Pregene Science and Technology Company, Ltd. · The Pregene (ShenZhen) Biotechnology Company, Ltd. · The Second Hospital of Hebei Medical University · Zhujiang Hospital

Trials 24 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 09 trials
Phase 0 NCT07435779 Feb 2026 → Feb 2027 expected Hebei Senlang Biotechnology Inc., Ltd. Recruiting No outcome recorded
Phase 0 NCT06681337 Nov 2024 → Dec 2025 overdue lupus nephritis Bioray Laboratories Not yet recruiting No outcome recorded
Phase 0 NCT06680388 Nov 2024 → Dec 2027 expected autoimmune disease Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 0 NCT04626765 Apr 2020 → Mar 2023 childhood acute lymphoblastic leukemia Hebei Senlang Biotechnology Inc., Ltd. Unknown No outcome recorded
Phase 0 NCT04626726 Apr 2020 → May 2023 B-cell adult acute lymphocytic leukemia Hebei Senlang Biotechnology Inc., Ltd. Unknown No outcome recorded
Phase 0 NCT04626739 Apr 2020 → Mar 2023 non-Hodgkin lymphoma Hebei Senlang Biotechnology Inc., Ltd. Unknown No outcome recorded
Phase 0 NCT04169932 Nov 2019 → Nov 2022 B-cell non-Hodgkin lymphoma Shanghai Longyao Biotechnology Inc., Ltd. Unknown No outcome recorded
Phase 0 NCT04184414 Jan 2018 → Jan 2020 B-cell acute lymphoblastic leukemia, follicular lymphoma, mantle cell lymphoma PersonGen BioTherapeutics (Suzhou) Co., Ltd. Unknown No outcome recorded
Phase 0 NCT03407859 Jan 2016 → Dec 2024 therapy-related myeloid neoplasm Zhujiang Hospital Unknown No outcome recorded
Phase 14 trials
Phase 1 NCT05585996 Aug 2022 → Nov 2025 B-cell non-Hodgkin lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded
Phase 1 NCT04012892 May 2019 → Apr 2021 non-Hodgkin lymphoma Chinese PLA General Hospital Unknown No outcome recorded
Phase 1 NCT04012879 May 2019 → Apr 2021 acute lymphoblastic leukemia Chinese PLA General Hospital Unknown No outcome recorded
Phase 1 NCT03559439 Apr 2018 → Nov 2021 B-cell acute lymphoblastic leukemia Shanghai Tong Ren Hospital Unknown No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT03232619 Aug 2018 → May 2020 acute leukemia Bioray Laboratories Completed No outcome recorded
Phase 1/2 NCT03263208 Aug 2017 → Jan 2019 B-cell acute lymphoblastic leukemia Henan Cancer Hospital Unknown No outcome recorded
Phase 1/2 NCT03146533 May 2017 → Apr 2019 B-cell neoplasm Shenzhen Second People's Hospital Unknown No outcome recorded
Phase 1/2 NCT02134262 May 2014 → Mar 2017 B-cell non-Hodgkin lymphoma Jichi Medical University Unknown No outcome recorded
Phase not applicable7 trials
NCT06993493 Feb 2025 → Aug 2027 expected autoimmune disease Beijing Boren Hospital Recruiting No outcome recorded
NCT06983964 Feb 2025 → Feb 2027 expected autoimmune disease Beijing Boren Hospital Recruiting No outcome recorded
NCT05618041 Sep 2022 → Sep 2027 expected acute lymphoblastic leukemia, plasma cell myeloma Hebei Senlang Biotechnology Inc., Ltd. Recruiting No outcome recorded
NCT04796441 Dec 2020 → Dec 2021 acute myeloid leukemia Hebei Senlang Biotechnology Inc., Ltd. Unknown No outcome recorded
NCT04792593 Dec 2020 → Dec 2021 Hebei Senlang Biotechnology Inc., Ltd. Unknown No outcome recorded
NCT04546893 Sep 2020 → Sep 2022 Hebei Senlang Biotechnology Inc., Ltd. Unknown No outcome recorded
NCT02813837 Jun 2015 → Jan 2021 lymphoid leukemia, lymphoma Innovative Cellular Therapeutics Co., Ltd. Unknown No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 24 sources stand behind the page.

FieldValueCited text
Known as CD19 CAR-T “This study is a single center, open label exploratory clinical trial aimed at evaluating the safety and efficacy of universal CD19 CAR-T therapy in subjects with autoimmune diseases.” NCT06983964
21

“Anti-CD19 CAR expressing T cells (CD19-CAR-T) will be expanded using a medium containing autologous plasma.” NCT02134262

“Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment in Relapsed/Refractory B-ALL” NCT03407859

CD19 CAR-TNCT05618041

NCT04546893

NCT04626739

NCT04012892

NCT07435779

NCT06983964

NCT06680388

NCT03232619

NCT03263208

NCT06681337

NCT03559439

NCT04184414

NCT03146533

NCT05585996

NCT06993493

NCT02813837

NCT04626765

NCT04626726

NCT04012879

Known as Anti-CD19 CAR expressing T cells Anti-CD19 CAR expressing T cells (CD19-CAR-T) will be expanded using a medium containing autologous plasma.” NCT02134262
Known as CAR-γδT ClinicalTrials.gov intervention name — accepted as the source's own label NCT04796441
Known as CD20 CAR-T CD20 CAR-TNCT05618041
1

NCT04169932

Known as Senl-h19 CAR-T ClinicalTrials.gov intervention name — accepted as the source's own label NCT04792593
Action Deplete “This kind of engineered T cells gains the ability to recognize antigen specific tumor cells and initiate the killing process” NCT03232619
Modality Cell therapy “autologous T cells genetically modified to express anti-CD19 Chimeric Antigen Receptor” NCT02134262
Route Intravenous “infusions of CD19CART cells into the vein” NCT02813837
Target CD19 CD19 targeted chimeric antigen receptor T cells therapy” NCT02813837